Podcasts about pediatric diabetes

Host: John Buse, MD, PhD Guest: Maria Jose Redondo, MD, PhD, MPH A recent paper focused on a variety of topics associated with type 1 diabetes, including its heterogenenity, endotypes, slowly progressive insulin-dependent diabetes, and the term type 1.5 diabetes. Dive into these topics with Dr. John Buse and Dr. Maria Redondo, Professor of Pediatrics in the Division of Pediatric Diabetes and Endocrinology at Baylor College of Medicine in Texas.

Dr. Kimber Simmons (MD, MS) is an Assistant Professor of Pediatrics at the Barbara Davis Center for Diabetes in Aurora, CO. She cares for children with Type 1 diabetes (T1D) and other endocrinologic disorders. She is passionate about educating families and the community about T1D. As a child, she prayed every night for a cure for T1D, and now she spends much of her time conducting research with the goal of contributing to the prevention of and, ultimately, a cure for T1D! She is involved in efforts to identify children who have T1D early, before they develop symptoms, and is an active investigator in many prevention trials, including those run by TrialNet. As a collegiate athlete who loves hiking, running, and spending time outdoors with her husband and two young children, she is sympathetic to the blood sugar roller coaster and enjoys helping young athletes learn to manage their blood sugars better. She is honored to be part of such a dedicated and innovative group of individuals committed to making positive changes for people at risk for and living with T1D!Ask the Experts: https://www.asktheexperts.org/Enable:  https://type1testing.enablebiosciences.com/Ask: https://www.askhealth.org/childhood-diabetesSupport the show

What are the latest recommendations for anxiety screening in the primary care setting? Find out about this and more in today's PV Roundup podcast.

In this episode, Stuart Weinzimer, MD sits down with hosts for a discussion on his research and experience with diabetes technology, the need to focus on patient-reported outcomes in pediatric diabetes, and strategies for meeting the practical needs of individuals with diabetes.

It's in the News.. the top diabetes stories of the past seven days. This week: new research looks at off-label use of GLP and SGLT drugs for people with type 1, Medtronic gets 780G approval in Canada, finger prick early detection of type 1, and lots going on for Diabetes Awareness Month. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX And by my new book “Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes” available on Amazon now. XX Our top story this week, Researchers say a blood test for early diagnosis of type 1 diabetes can stave off serious illness and hospitalization in children. This Australian study looked at the finger prick sample that is collected in the home and mailed to the lab. It included more than 17-thousand children and young adults, mostly in families with a history of type 1. The team of researchers are the first to use this method to screen diabetes in Australia. They said, We want to make type 1 diabetes screening accessible to every Australian child no matter where they live. Our recent work has proven that we can do this cheaply, accurately, and conveniently," The study is published in Pediatric Diabetes. https://medicalxpress.com/news/2022-11-home-screening-diabetes.html XX Medtronic gets the okay from Canada for it's MiniMed 780G system. It's now available in more than 60 countries around the world, with the U.S. notably missing from the list. Current 770G users will be able to upgrade their devices with the new system's software. The MiniMed 780G is equipped with Medtronic's SmartGuard technology, a hybrid closed-loop system what works with Medronic's CGM. It's approved for ages 7-80. Medtnoic submitted to the FDA in the spring of 2021, nearly a year after securing CE mark approval in Europe. The U.S. sign-off has been slow to arrive, however, thanks in large part to the FDA's discovery of quality control issues at the California headquarters of Medtronic's diabetes business. A December 2021 letter from the agency outlined shortfalls it discovered at the Los Angeles-area facility in a routine inspection, prompting Medtronic to implement corrective actions and other process improvements to address the issues. https://www.fiercebiotech.com/medtech/still-awaiting-us-approval-medtronics-auto-adjusting-insulin-pump-lands-canadian-nod XX XX People with type 1 diabetes who take GLP-1 receptor agonists or SGLT-2 inhibitors in real life seem to line up with controlled trials. The GLP-1 medicines have brand names like Ozempic or Trulicity and the SGLT-2 are Invokana or Jardiance. These are newer medications and people with type 1 are cautioned to take them carefully because of the higher risk of DKA. However, these researchers say after 12 months of use people taking a GLP-1 receptor agonist had a significant reduction in glycated hemoglobin (HbA1c), from an average of 7.7% to 7.3% (61 to 56 mmol/mol), as well as in bodyweight, from an average of 90.4 to 85.4 kg. and they used less insulin overall. SGLT2 inhibitors were used by 39 study participants for an average duration of 24.2 months, mostly with the intent to achieve better glycemic control (73.3%), but also for weight loss (37.8%), reduced insulin requirements (26.7%), and reduced glucose variability (24.4%). Also, about 12% of users initiated SGLT2 inhibitors for their beneficial cardiovascular or renal properties. In line with clinical trial findings, these real-world users had significant reductions in average HbA1c after 12 months of use, from 7.9% to 7.3% (63 to 56 mmol/mol), and in basal insulin dose, from a daily average of 31.3 to 25.6 units, but not in bolus insulin. And contrary to the results of controlled trials, although SGLT2 inhibitor users had a weight reduction, this was small and not statistically significant, at an average of 89.2 and 87.5 kg before and after 12 months, respectively. https://www.medwirenews.com/diabetes/real-world-adjunctive-medication-outcomes-type-1-diabetes/23662504 XX Taking a personalized approach to kidney disease screening for people with type 1 diabetes (T1D) may reduce the time that chronic kidney disease (CKD) goes undetected. The finding, published in Diabetes Care(link is external), provides the basis for the first evidence-based kidney screening model for people with T1D. Current CKD screening recommendations include annual urinary albumin excretion rate (AER) testing for anyone who has had T1D for at least five years. The new findings suggest that AER screening could be personalized to optimize testing frequency and early detection of CKD. Specifically, people with T1D who are at low risk of developing CKD could be tested for AER less frequently to reduce burden and cost, and those at high risk for CKD could be tested more frequently to facilitate earlier CKD detection. People with T1D have an estimated 50% risk of developing CKD over their lifetime. Important to note, these numbers and this study is based on 30 years of data, dating back to the landmark DCCT trial. https://www.nih.gov/news-events/news-releases/nih-funded-study-finds-personalized-kidney-screening-people-type-1-diabetes-could-reduce-costs-detect-disease-earlier XX Lots of stuff happening for diabetes awareness month. Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced it will ring the opening bell at Nasdaq on November 1, 2022, in recognition of National Diabetes Awareness Month. “We are proud to celebrate this year's Diabetes Awareness Month by ringing the Nasdaq Opening Bell with representatives of several organizations that make diabetes, and supporting the people who are living with diabetes, their sole focus,” said Devdatt “Dev” Kurdikar, president and chief executive officer of embecta. “Our company is honored to recognize the patients, caregivers, healthcare providers, and advocacy organizations working together to improve access to education and progress toward the vision of a life unlimited by diabetes.” embecta also recognizes the 100-year milestone of the first successful injection of insulin that was administered to a person with diabetes. Today, 1 in 10 adults around the world live with diabetes1, an estimated 537 million people, and almost half don't know they have it. “Our community often faces stigma and isolation associated with diabetes as we frequently practice self-management of the disease,” said Anna Norton, chief executive officer of DiabetesSisters. “Increased access to education and resources that will improve the standard of care and quality of life across the community is essential, and we're proud to stand with embecta to share in this mission.” The bell ringing ceremony will be streamed live via Nasdaq's Facebook page. Additionally, highlights from the ceremony will be shared across embecta's social media channels. Please visit embecta.com for additional information regarding Diabetes Awareness Month. About embecta embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com. XX Dexcom has teamed up with ESPN's Adam Schefter – his wife has type 1 – to launch Dexcom U, the first-ever NIL (name, image, likeness) program designed to celebrate college athletes with diabetes and inspire people with diabetes who have athletic dreams of their own. NIL is name image likeness, it's the new program that allows college athetes to be paid. Dexcom says According to a recent study, nearly half (43%) of adults with Type 1 diabetes felt like quitting sports and physical activities because of their diagnosis, and one in five (20%) went through with quitting. These athletes tell their stories and how Dexcom helps them. I'll link up the video and we are set to speak with some of them in the next couple of weeks. XX A new study released by the American Diabetes Association® (ADA), illustrates the significant barriers that low-income Americans, people of color, older Americans, and people with diabetes living in states with the highest prevalence of the disease face in accessing continuous glucose monitors (CGM). These barriers are especially high for Americans on Medicaid, who are the least likely to have access to a CGM. CGMs continually monitor blood glucose (blood sugar), giving real-time updates. The devices provide significant, potentially life-changing benefits for diabetes management, and in turn for the avoidance or delay of serious co-morbidities, hospitalizations, and even death. “It is disappointing to see that access to vital diabetes management tools like CGMs often depends on your income, the color of your skin, your age, and where you live,” said Dr. Robert Gabbay, chief scientific and medical officer at the ADA. "The ADA is committed to addressing access barriers—such as inadequate health insurance coverage, steep Medicare and Medicaid coverage requirements, and physician shortages—to ensure that everyone who can benefit from a CGM can get one.” The ADA is working with the Centers for Medicare and Medicaid Services, state Medicaid programs, and Congress to eliminate barriers people face in accessing diabetes technology like CGMs. The CGM study is available on the ADA's website. XX Diabetes on Nasdaq XX Great start to a blog post by Tim Street, he writes over at DiabeticTech. He's trying out 6 CGMs currently on the market. Dexcom ONE Medtrum Nano Dexcom G6 Glucomen Day GlucoRX Aidex Freestyle Libre2 You can check out his blog to see the photos of him wearing all of the CGMs and hear his methods for testing. https://www.diabettech.com/cgm/unboxing-and-applying-the-six-cgms/?utm_source=dlvr.it&utm_medium=facebook XX Dexcom also has a See Diabetes campaign for this month which gives you a chance to create your own overlay patch. I've created one for the show, you can it on social along with others with the #SeeDiabetes hashtag. Patti LaBelle, Mark Andrews and Nick Jonas are taking part.. If you design an overlay – I'll put the link in the show notes – you may be order a few for free – they're saying limited supply. A cynic would say this is a creative way to use up the G6 overlay patches before the G7 comes out but.. personally I think it's a really creative and fun idea. I like how mu patch came out, but I doubt my son will wear it! XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX XX XX On the podcast next week.. Tom from Type One Talks The past episode was all about thinking through your use of CGM, questions to ask of yourself, your family and anyone with whom you plan to share. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

  Vidcast:  mhttps://youtu.be/Qewnjskshlc   Contracting CoVid doubles the risk that a child will develop insulin-dependent diabetes.  This the result of a matched cohort study completed by health informatics researchers at Cleveland's Case Western Reserve University.   The study population included more than one million children under age 18 with 29% having contracted CoVid infections and 71% having contracted non-CoVid respiratory infections.  By 1, 3, and 6 months following their respective infections, those with CoVid histories had increased risks of type one diabetes that were 1.96, 2.1, and 1.8 fold higher than the controls.  The risks were higher for older children: for kids 0 to 9 years, CoVid bumped the risk of diabetes by 6 months 1.7 fold while for that 10-18 years that risk jumped 2.2 fold.   The take-home points are two-fold.  First, children infected with CoVid should be carefully monitored for the development of diabetes.  Finally, parents should do all they can to prevent their kids from getting a CoVid infection.   https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796649   #diabetes #CoVid #insulin  

Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDCES and Michelle Magee, MD, MB, BCh, LRCPSI join us to talk about the importance of preparation, risk mitigation, and treatment of hypoglycemia for school-age children. We want to thank our sponsor, Lilly Diabetes, for their support of this episode. VV-MED-124888 © 2022 Lilly USA, LLC. All rights reserved.

In this episode, listen as Taryn Vaeth, a pediatric nurse practitioner discusses pediatric diabetes, and covers how nutrition, behavior management, and knowledge of the latest medication and technology are one of the many tools used to help patients.

On this Flusterclux In Session episode, anxiety expert Lynn Lyons talks to a mom who is managing a tricky combination of factors: her own worry, her daughter's worry, and her daughter's chronic illness. Knowing the difference between what worry demands and how to manage a serious condition (like type 1 diabetes or anaphylaxis-causing allergies) can be hard to discern. But it's a skill families must learn together when your child's mental and physical health are on the line.Flusterclux  Retreat for Parents And TeensRegistration Open until April 3!Equipping Teens To Launch: The Connections, Conversations, and Skills Families NeedSpecifically for families with teens aged 13-19, Lynn Lyons and Robin Hutson of Flusterclux will present a full day of programming on Saturday, April 9th, 2022, from 9am until 5pm at the Woodstock Inn in Woodstock, Vermont.  The Latest Course for Parents!Managing Anxiety in Children: A Guide for ParentsThis self-paced course covers the core tools a family needs to manage their anxiety, the same principles Lynn teaches to families in her private practice.This course includes 6 video modules from Lynn Lyons, LICSW, and 9 additional Q&A videos from Lynn and Robin of Flusterclux.What you'll get:Understand how anxiety works so that you can help manage your kids and your own.Learn what to say when anxiety shows up for you or your kids.For Kids: A special video that explains how anxiety works suitable for those ages 6 and up. Follow UsJoin the Facebook group to get news on the upcoming courses for parents, teens, and kids.Follow Flusterclux on Facebook and Instagram.Follow Lynn Lyons on Twitter and Youtube.New episodes arrive Friday at 6:00AM EST.

New information about kids with type 1 and COVID, a possible link between pollution and type 2, a look at Dexcom's latest earnings call and a lot more. We're trying something new for the next few weeks! Join Stacey live every Wednesday on Facebook for the top diabetes news and headlines or listen back via the podcast or on other social outlets. Full transcription and links/sources below. Watch the replay on our Facebook page or YouTube Channel Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android   Podcast intro: Hi all! This episode is very different. Instead of a classic episode, I wanted to try something new. What you’re about to hear first aired live on our FB page. Join me every Wednesday this month at 4:30pm eastern for DC the news! -- Hi, I’m Stacey Simms, the host of what’s usually a weekly podcast providing info & inspiration for people with diabetes with a focus on people who use insulin. I’m trying something new. A short newscast full of the top diabetes news of the past week. And that’s all types of diabetes. We’ll debut here on FB Live and then share on other outlets, including the podcast. The goal here is to get you up to speed – quickly – with good info. And let’s not forget.. Diabetes Connections The News is brought to you by Inside the Breakthrough. A new history of science podcast full of “Did You Know Stuff” Now..  let’s start! In The News… XX The majority of children with type 1 who tested positive for COVID.. did just fine. According to the very first report about this, from Barbara Davis Center, 77% of children with type 1 who had COVID were cared for at home, without complications. The children who were hospitalized were all diagnosed with diabetic ketoacidosis and the greatest risk for adverse outcomes was an A1C over 9. Fewer than 2% of all these cases required any respiratory support, and no deaths were recorded. Kids with T1D and covid fared well: https://www.medscape.com/viewarticle/950277 XX Another study about kids and covid.. The incidence of severe diabetic ketoacidosis among children presenting with new-onset type 1 diabetes doubled during the pandemic period compared with 2019, according to data published in Pediatric Diabetes. This research comes clinics in Canada from March to August 2020 and compared to the same period in 2019. The number of children diagnosed with T1D was similar but the frequency of DKA went from 45% to 68%. What they called severe DKA went from 13% to 27%. Speculation here is that fear of COVID kept people out of the doctor’s office until it was absolutely necessary, but these researchers say more education is needed around DKA even after the COVID pandemic ends. More severe DKA in kids during covid: https://www.healio.com/news/endocrinology/20210422/severe-dka-at-type-1-diabetes-diagnosis-doubles-during-pandemic XX Hat tip to chris Wilson for this.. Dexcom had it’s first quarter earnings call last week. Still expecting G7 to launch in Europe ahead of the US, with US launch towards the end of the year. We’ll find out more details about the G7 at ATTD conference this summer. That’s the advanced technologies and treatments for diabetes conference. Chief Operating Officer Quentin Blackford also reports that quote, “we rolled out an update to the G6 algorithm in the first quarter. We believe this update will drive further reductions to times in which data is temporarily unavailable And I've seen excellent results from the initial launch of this updated algorithm in Canada in 2020.” I’ve talked to Dexcom a few times about how they can make changes to the transmitters and sensors that don’t require regulatory approval – no announcement they just roll them out. Looks like this was one of these. https://www.fool.com/earnings/call-transcripts/2021/04/29/dexcom-inc-dxcm-q1-2021-earnings-call-transcript/ XX Looking at type 2.. A new study suggests that people exposed long-term to certain air pollutants may have a higher risk of diabetes. This was part of the ongoing Jackson Heart Study which looks at African American patients in Mississippi. The study included more than 5000 people ages 21 to 94 in the Tri-County Jackson area.. where traffic is the major source of ambient air pollution. Levels of diabetes and of pollution exposure were assessed 1 and 3 years prior to visits 1 and 2. They reported a diabetes prevalence of 21.8% at visit 1 and 33.2.% at visit 2. Furthermore, 12.5% of those without diabetes at visit 1 developed it by the second visit. Theses researchers say the results provide some evidence that the exposure is linked to diabetes. Apparently there are very few studies of environmental pollution risk factors in communities of color – these researchers say more follow up is needed. Air pollutants and type 2 diabetes: https://www.hcplive.com/view/air-pollutants-associated-diabetes-prevalence -- Quick note about gestational diabetes. Turns out few women who meet the criteria for early gestational diabetes screening receive it. This study was only done at one location, but the authors say it’s indicative of a greater problem. Only 12% of women who met the American College of Obstetricians and Gynecologists’ criteria for early gestational diabetes screening actually received it at a New York hospital. It’s recommended that all pregnant women be screened for gestational diabetes (GDM) at 24 to 28 weeks. Nearly one-fifth of the women who met the criteria for early screening but were not screened were ultimately diagnosed with gestational diabetes further along in their pregnancy. https://www.healio.com/news/primary-care/20210501/few-women-who-meet-criteria-for-early-gestational-diabetes-screening-receive-it XX Quick break – want to tell you about one of our great sponsors who helps make Diabetes Connections possible. Inside the Breakthrough explores the idea of a “Eureka” moment. It’s historical wisdom mixed with modern insight – a little bit history show, little bit science show. The latest episode tells the story of Dr. Banting and the discovery of insulin. Every week is a different story – they’ve talked about snake oil and leaded gasoline & crime – but this week has info about the discovery of insulin that I’d never heard.. Banting had to sell his car to get money to buy dogfood. And of course, there’s scientific info as well. Listen to Inside the Breakthrough wherever you listen to podcasts.. XX Back to the news.. one of the pioneers of diabetes technology passed away this week. Helen Murray Free co-developed the dip-and-read diabetes test, a paper strip that detected glucose in urine. She died on Saturday at the age of 98.  Before the invention of the dip-and-read test in 1956, technicians added chemicals to urine and then heated the mixture over a Bunsen burner. The test was inconvenient, and, because it could not distinguish glucose from other sugars, results were not very precise. Ms. Free and her husband figured out how get strips of filter paper to turn blue when glucose was present. The test made it easier for clinicians to diagnose diabetes and cleared the way for home test kits, which enabled patients to monitor glucose on their own. https://www.nytimes.com/2021/05/03/science/helen-murray-free-dead.html And finally, big book launch this week – Chris Ruden is out with The Upper Hand: Leveraging limitations to turn adversity into advantage. Chris is one of our favorite guests – he’s been on the podcast a couple of times. Chris was born with 2 fingers on his left hand and a shorter left arm. He was diagnosed with type 1 at age 19. He’s a champion power lifter – he’s been on the Titan Games and got a big hug from The Rock – and he’s out with a new book. Again it’s called The Upper Hand.. Congrats Chris! XX That’s our first Diabetes Connections – The News. I’m going to do this for about a month and see what the response is. If you like it, share it. And feel free to send me your news tips. Stacey @ diabetes dash connections dot com. Please join me wherever you get podcasts for our next episode -Tuesday – we’re talking to the folks from Zealand Pharmacy about the newest shelf ready emergency glucagon -Zegalogue Thanks and I’ll see you then!

Emily Coppedge N.P. discusses The Pediatric Diabetes Program at Weill Cornell Medicine. She shares tips for parents on catching the symptoms of early-onset diabetes in kids and offers guidance on how to make healthy choices for the whole family to help their children thrive.

Dr. Abby Hollander is a Professor of Pediatrics and Diabetes at Washington University School of Medicine in St. Louis. She is Board certified in Pediatrics and Pediatric Endocrinology. Dr. Hollander’s clinical interests include all pediatric endocrine disorders and diabetes mellitus. She has a focused interest in treatment of endocrine problems in children with brain tumors and has been a member of the multidisciplinary neuro-oncology team for St. Louis Children’s Hospital for over 15 years. Dr. Hollander participates in clinical research regarding growth disorders in children with neurofibromatosis and is co-leader of a multidisciplinary team providing care for children with disorders of sex development and adolescents with gender dysphoria.Diabetes at Camp course for CME credit (6.5 hours for doctors, nurses, dietitians, pharmacists) can be accessed on the American Diabetes Association website, URL: www.ada.healthmonix.com, under E-learning, look for Diabetes at Camp.

AADE Pediatric Diabetes Resources: DiabetesEducator.org/pediatricsChildren with Diabetes: childrenwithdiabetes.comFriends for Life Conferences: childrenwithdiabetes.com/conferencesDiabetes Patient Advocacy Coalition (DPAC): diabetespac.org

AADE's new resources and practice paper for pediactric diabetes: DiabetesEducator.org/pediatrics American Diabetes Association's Camp Page: https://www.diabetes.org/community/camp Diabetes Education and Camping: https://www.diabetescamps.org/

Jake A. Kushner M.D., Medical Director, McNair Interests, provides a thorough overview of his research and study of diabetes. Currently, Dr. Kushner serves as the Medical Director for McNair Interests. He is a renowned diabetes researcher as well as a pediatric endocrinologist with a particular expertise in biotechnology, biomedical research, type 1 diabetes and other specific endocrine disorders. Dr. Kushner is the former Chief of Pediatric Diabetes and Endocrinology and McNair Medical Institute Scholar at the Baylor College of Medicine and Texas Children's Hospital. He has worked with the National Institutes of Health, served on the type 1 diabetes advisory council for Lexicon Corporation, and been a strategic advisor for Sanofi. Dr. Kushner discusses his background as a pediatric endocrinologist and how he came to be interested in the research and study of diabetes. Dr. Kushner is a respected, nationally recognized expert in type 1 diabetes research. His background in medicine is significant and includes endocrinology and diabetes, specifically caring for children with type 1 diabetes, as well as cystic fibrosis-related diabetes, and treating children who have hypoglycemia. He explains type 1 diabetes, and talks about how it affects many people worldwide.  Dr. Kushner delves into the complex issue of insulin and how the body reacts and responds to nutrients. He explains in detail, the storage of glucose, carbohydrates, and how the body processes everything that comes into it, as well as how stress affects everything. He talks at length about the kinds of meals that people eat, and explains how specific foods are processed by the body for use, including what the body needs, especially for those who have special dietary requirements due to health conditions or disease. Dr. Kushner is a UC Berkeley graduate and earned a medical degree from Albany Medical College in New York. Dr. Kushner completed his medical residency in pediatrics at Brown University. Additionally, Dr. Kushner engaged in a clinical fellowship at Children's Hospital Boston and a prestigious research fellowship at the Joslin Diabetes Center, the world's largest diabetes research center, at Harvard Medical School in Boston. 

A family history, working with children, and a love of math motivated Radhika Muzumdar, MD, chief of Pediatric Endocrinology, to choose a career focused on diabetes. Her research and clinical care aim to meet the short- and long-term goals of treatment and management of diabetes. In this episode, Dr. Muzumdar covers her career beginning with her earlier work on growth hormones and IGF-1 (insulin-like growth factor 1), to her upcoming studies on the hypothalamus and the humanin peptide. Other current programs and studies include a mobile test kitchen and video game-based nutrition education.

November is National Diabetes Month, and this month Dr. Aaron Carroll, is talking to Dr. Raghu Mirmira. Dr. Mirmira is the Eli Lilly Professor in Pediatric Diabetes and Director of the Diabetes Research Center at Indiana University Health in Indianapolis, IN. You'll learn about Type I and Type II diabetes, and the ways people develop the disease.  The Healthcare Triage podcast is sponsored by Indiana University School of Medicine whose mission is to advance health in the state of Indiana and beyond by promoting innovation and excellence in education, research and patient care. IU School of Medicine is leading Indiana University's first grand challenge, the Precision Health Initiative, with bold goals to cure multiple myeloma, triple negative breast cancer and childhood sarcoma and prevent type 2 diabetes and Alzheimer’s disease.

This week's episode of the 180º of Impact podcast features Matt Scott's conversation with Erik Douds, founder of Diabadass and Diabetes Abroad, as well as the Douds Fund for Pediatric Diabetes. Follow Erik on Twitter @ErikDouds and visit www.diabadass.com. For more on 180º of Impact, visit www.lets.care and follow @LetsYouCare on social media. --- Send in a voice message: https://anchor.fm/letsyoucare/message

Author: Chris Holmes, MD Educational Pearls:   There is a risk of cerebral edema in pediatrics with DKA if over resuscitated. Recent study comparing normal saline vs. ½ normal saline showed no difference in rates of cerebral edema regardless of rate of infusion. Recommend sticking with a fluid resuscitation protocol you are familiar with (i.e., 2 rounds of 10cc/kg bolus of NS).   References Glaser, N. S., Ghetti, S., Casper, T. C., Dean, J. M., & Kuppermann, N. (2013). Pediatric Diabetic Ketoacidosis, Fluid Therapy and Cerebral Injury: The Design of a Factorial Randomized Controlled Trial. Pediatric Diabetes, 14(6), 435–446. http://doi.org/10.1111/pedi.12027  

Dr. Jake Kushner is leading the efforts in Diabetes and Endocrinology at Texas Children's Hospital. Dr. Kushner is a McNair Medical Institute Scholar at the Baylor College of Medicine. As the Chief of Pediatric Diabetes and Endocrinology at Baylor College of Medicine, he is a major thought leader in type 1 diabetes care and research. His overarching career goal is to help children and young adults with diabetes and other endocrine disorders live long, healthy lives. His administrative priorities focus upon developing and promoting innovative new models of patient-centered care, education, and cutting edge research. A graduate of the University of California at Berkeley, Dr. Kushner earned his medical doctorate from Albany Medical College in New York. He completed a residency in pediatrics at Brown University. He then completed a clinical fellowship in Pediatric Endocrinology at Children's Hospital Boston, Harvard Medical School, followed by a 5-year research fellowship at the Joslin Diabetes Center at Harvard Medical School. Prior to arriving at the Baylor College of Medicine Dr. Kushner was at the University of Pennsylvania School of Medicine and the Children's Hospital of Philadelphia (CHOP). Dr. Kushner has received national awards, including elected membership to the prestigious American Society of Clinical Investigation. He currently serves as the president of the Society for Pediatric Research. Dr. Kushner's research has been supported by the National Institutes of Health, the Juvenile Diabetes Research Foundation and the March of Dimes, amongst other sources. His clinical interests include the care of children with type 1 diabetes. Dr. Kushner's research is focused upon of the insulin-secreting beta cells of the pancreas. A major theme of the Kushner lab includes studies to understand the origins of adult beta cell growth and regeneration. Until recently it was not clear exactly where adult beta cells came from during postnatal life. Dr. Kushner and colleagues have carried out studies in adult mice with a variety of advanced tools. In contrast to the dominant views, they do not observe any contribution to beta cell growth in adult mice from "tissue stem cells". Instead, they find that beta cells expand by simple division "self-renewal". Dr. Kushner and colleagues are currently extending this work, with the goal of studying beta cell regeneration under a variety of normal and disease conditions. In This Episode We Discuss: The intricacies of type 1 diabetes Beta cell dysfunction Nutritional approaches to type 1 diabetes: standard care and carbohydrate restriction Issues with low-carb for T1D: hypoglycaemic episodes? ketones? long-term safety unknown? "Low carb is not for everyone with T1D. Frankly, there is so much that we don’t know. But, low carb management of T1D can be quite advantageous for those who choose it." - Jake Kushner, MD

EP 30: 3: Pediatric Diabetes Mia and Ruth Carrasco 1 by Dr. Barbara Taylor Cox

EP 30: 2: Pediatric Diabetes Treatment and Management by Dr. Barbara Taylor Cox

EP 30: 1: Pediatric Diabetes Symptoms and Diagnosis by Dr. Barbara Taylor Cox

EP 30: 4: Pediatric Diabetes Mia and Ruth Carrasco 2 by Dr. Barbara Taylor Cox

Premature Cardiovascular Disease in Pediatric Diabetes f/ Steve Willi, MD, University of Pennsylvania

Host: Linda Bernstein, Pharm.D. In this edition of The Pharmacy Report®, host Dr. Linda Bernstein spotlights type 1 diabetes and the new paradigms of research in disease detection, prevention and treatment. In the Movers and Shakers segment, Dr. Stephen E. Gitelman, M.D., Professor of Clinical Pediatrics and Chair of Pediatric Diabetes and Clinical Research at the University of California, San Francisco shares his fascinating path of discovery and research into this complex disease and how someday it could revolutionize therapeutic approaches for not just the patient, but at-risk family members as well. References mentioned in this segment: Diabetes Center, University of California, San Francisco Centers for Disease Control and Prevention's 2013 Tips From Former Smokers campaign, including 1-800-QUIT NOW, a number that links callers to their state quitlines. The website is www.cdc.gov/tips and features information on the campaign, as well as information on how to quit smoking from the National Cancer Institute's www.smokefree.gov

Raghu Mirmira, MD, PhD Lilly Foundation Professor in Pediatric Diabetes, Department of Pediatrics Indiana University "Islet Beta Cell Dysfunction in Diabetes: Too Much Hype-Usination?" Thursday, February 21 9:00 AM Russ Berrie Pavilion, 1st Floor Conference Room

Welcome back for another great episode of Low-Carb Conversations With Jimmy Moore and Friends! Today Jimmy and Mindy are joined by Paleo blogger Badier Velji and MMA athlete Sally Krumdiack. They talk about recent developments in the battle against Childhood Obesity and a great recipe for spaghetti squash with meat sauce. So go grab a cup of coffe, pull up a chair and join us on the Virtual Porch for some great low-carb chin wagging! LINKS MENTIONED IN EPISODE 24- Support our sponsor: - - - - - -  Recipe: Makes 2-3 normal servings or 1 post- serving All ingredients are from Trader Joe’s, but any store will do Ingredients: 1 lb grass-fed ground beef 2 tbsp coconut oil (not from TJs, but you can find it at Whole Foods or online 1 jar Tomatillo and Roasted Yellow Chili Salsa 3 tsp cumin 1/2 tsp black pepper 1/4 tsp salt dash of oregano 1 spaghetti squash Directions: Poke a number of holes into the spaghetti squash with a fork to release pressure while cooking. Put the squash in the microwave for 15 minutes, rotating every 3. At the same time, brown the ground beef on medium in a skillet with 3 tbsp of coconut oil. When the beef is halfway done, add the cumin, pepper, salt and oregano. Finish browning the beef, turn the heat to low, and add the jar of salsa. Let this simmer for an additional 5-10 minutes until it thickens. When the spaghetti squash is done, remove it from the microwave (carefully, it will be hot). Slice off the end caps and cut in half length wise. With a fork, remove the seeds and fibers from the center. Again with a fork, scrape the remaining squash into a new container. Here, you can choose to continue cooking the squash in the microwave with additional oil for 15 more minutes, or pan fry it. The consistency should be soft with a slight crunch to it. When done, the beef can be served on the bed of squash or mixed together, either hot or cold.

Guest: Alberto Hayek, MD Host: Steven Edelman, MD Diabetes research is the cornerstone for new opportunities in the treatment of patients living with diabetes. How will the newly formed Pediatric Diabetes Research Center serve this goal? Join guest host, certified diabetes educator Janice Baker and Dr. Alberto Hayek, professor of pediatrics and co-director of the UC San Diego's Pediatric Diabetes Research Center, as they discuss the need for collaboration in both biochemistry, molecular and cell-based therapies for the treatment of diabetes.